KLRA vs VKTX
KLRA: A clinical-stage biotech developing a diversified pipeline of GLP-1-based obesity management drugs, led by a dual GLP-1/GIP agonist injectable designed to deliver superior weight loss potential. VKTX: Viking is developing VK2735, a novel dual GLP-1/GIP receptor agonist in Phase 3 trials for obesity and metabolic disorders, targeting a high-growth market currently dominated by single-agent GLP-1 therapies.
Side-by-side fundamentals
| Metric | KLRA | VKTX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $17.79 | $37.31 | |
| Market cap as of 2026-07-23 | $2.4B | $4.3B | |
| PEG as of 2026-07-23 | n/a | -0.04 | |
| ROE as of 2026-07-23 | -23.4% | -71.3% | KLRA higher |
| ROA as of 2026-07-23 | -21.5% | -65.3% | KLRA higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Beta as of 2026-07-23 | 1.68 | 0.65 | |
| 1-year return as of 2026-07-22 close | -29.2% | +16.2% | VKTX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.